Savara (SVRA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SVRA Savara

Watchlist

3.360
-0.110-3.17%

Close Nov 29 13:00 ET

3.360
0.0000.00%

Post 17:02 ET

576.64MMarket Cap-7813P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)
Yahoo FinanceNov 25 09:18 ET
Savara Announces New Employment Inducement Grant
BusinesswireNov 22 16:05 ET
Savara Announces Encore Presentation of Results From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the British Thoracic Society Winter Meeting 2024
BusinesswireNov 22 08:05 ET
Express News | Savara Announces Encore Presentation of Results From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the British Thoracic Society Winter Meeting 2024
ReutersNov 22 08:05 ET
Independent Director of Savara David Ramsay Buys 4.5% More Shares
Simply Wall StNov 21 05:06 ET
Insider Purchase: Director at $SVRA (SVRA) Buys 20,000 Shares
Quiver QuantitativeNov 20 08:00 ET

Comments

Jaguar8

Yesterday 15:14

🔵Watchlist Monday December 2. NFA. Trade the Chart. No emotions. No FOMO

This is a list in progress
NOTE:
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
3. NEVER open position without momentum.
4. If you are expecting all stocks to be a runner,then you are set for failure, losses, and bagholding. Not all good news run and not...

Trytosaveabit

Nov 22 07:08

Watching

$Savara (SVRA.US)$ Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
2 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from...

Jaguar8

Nov 22 07:07

NEWS

$Savara (SVRA.US)$
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Savara announced an encore presentation of Phase 3 IMPALA-2 trialresults for Molgramostim inhalation solution in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the upcoming British Thoracic Society Winter Meet...

Teddy123

Nov 12 07:26

In the pipeline

$Savara (SVRA.US)$
After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Savara. “BLA submission, coupled with the submission of the MAA to the EMA by the end of 2025, are major regulatory mileston...

Stock_Drift

Oct 22 07:32

$Savara (SVRA.US)$

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

SVRA Savara

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target